BCR-ABL-IN-5

Modify Date: 2024-01-09 16:33:18

BCR-ABL-IN-5 Structure
BCR-ABL-IN-5 structure
Common Name BCR-ABL-IN-5
CAS Number 1795736-60-5 Molecular Weight 494.37
Density N/A Boiling Point N/A
Molecular Formula C25H21Cl2N5O2 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of BCR-ABL-IN-5


BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].

 Names

Name BCR-ABL-IN-5

 BCR-ABL-IN-5 Biological Activity

Description BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].
Related Catalog
Target

IC50: 6.5 μM (K562)[1].

In Vitro BCR-ABL-IN-5 (compound II) (0-100 mM, 72 hours) can inhibit the proliferation of K562 human leukemia cells[1]. Cell Proliferation Assay[1] Cell Line: K562 human leukemia cell line Concentration: 0-100 μM Incubation Time: 72 hours Result: Inhibited K562 proliferation with an IC50 value of 6.5 μM.
References

[1]. Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.

 Chemical & Physical Properties

Molecular Formula C25H21Cl2N5O2
Molecular Weight 494.37